FDA Advisory Committee Agrees That Clinical Data Support The Efficacy And Safety Of Zostavax(TM), Merck & Co., Inc.'s Investigational Vaccine For Shingles, In Adults Aged 60 And Older

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Dec. 15, 2005--Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that the extensive data from clinical trials in more than 40,000 people support the efficacy and safety of ZOSTAVAX(TM) (zoster vaccine live (Oka/Merck)), the Company’s investigational vaccine, to prevent shingles in adults aged 60 and over.